Cancer - Prostate(구연) (E-148) 전립선암 환자의 삶의 질에서 류프로라이드 아세트산염의 영향 : 전향적 경도 코호트 연구 화순전남대학교병원 비뇨의학과교실 정승일, 구진석, 조현진, 송재익, 이호연, 김재현, 임도경, 김태희, 은성종, 오주용, 유성현, 김명수, 정호석, 황의창, 오경진, 김선옥, 강택원, 권동득, 박광성 Purpose: The health-related quality of life (HRQOL) information related to androgen deprivation therapy (ADT) is valuable in the treatment planning for prostate cancer (PC) patients. We aimed at investigating the impacts of leuprolide acetate on HRQOL of patients with PC. Materials and Methods: Patients were prospectively recruited from October 2018 to April 2020. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and PC-specific module (PR25) were administered before hormonal therapy (baseline) and at 3, 6, and 12 months after ADT. All patients received subcutaneous injections of 45 mg leuprolide acetate at 6-month intervals for 12 months. At each time point, HRQOL was compared, and a difference of 10 on a scale of 0–100 was considered clinically significant. Results: Fifty-five of 71 patients (77.5%) completed the 12-month study. Twenty-two of the 55 patients underwent intensity-modulated radiation therapy (IMRT) for 3 months. There was no difference in baseline characteristics according to IMRT. Compared to the baseline, physical function had deteriorated after 3, 6, and 12 months (p = 0.003, p = 0.001, and p <0.001, respectively), and role function had deteriorated after 3 months (p = 0.019). However, the global quality of life did not change over time. Symptom scales of EORTC QLQ-C30 indicated no statistically significant deterioration in symptoms. Results of QLQ-PR25 revealed that patients experienced an increase in hormonal treatment-related symptom after 3, 6, and 12 months (p = 0.002, 0.001, and 0.004, respectively). Conclusion: Results of this prospective study indicated that the leuprolide acetate treatment at 6-month intervals was accompanied by no change in the global quality of life despite deteriorations in the physical role and hormonal treatment-related symptoms. Adding IMRT to ADT showed no additional deterioration in HRQOL. keywords : Androgen deprivation therapy (ADT), Prostate cancer(PC), Health-related quality of life(HRQOL)